Cerus (NASDAQ:CERS) Lifted to Sell at BidaskClub

BidaskClub upgraded shares of Cerus (NASDAQ:CERS) from a strong sell rating to a sell rating in a research note issued to investors on Friday, January 5th.

A number of other research analysts also recently commented on the company. Cantor Fitzgerald reissued an overweight rating and issued a $5.00 price target on shares of Cerus in a report on Friday, January 5th. ValuEngine raised Cerus from a strong sell rating to a sell rating in a report on Thursday, January 4th. Zacks Investment Research downgraded Cerus from a buy rating to a hold rating in a report on Wednesday, January 3rd. BTIG Research reaffirmed a neutral rating on shares of Cerus in a report on Friday, December 8th. Finally, Robert W. Baird reaffirmed a buy rating and set a $5.00 target price on shares of Cerus in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Cerus presently has an average rating of Hold and a consensus target price of $5.83.

Cerus (NASDAQ CERS) traded down $0.05 during mid-day trading on Friday, hitting $4.32. The stock had a trading volume of 526,900 shares, compared to its average volume of 884,256. The firm has a market capitalization of $492.85, a price-to-earnings ratio of -7.32 and a beta of 1.93. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $4.70. The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. The firm had revenue of $10.80 million during the quarter, compared to the consensus estimate of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. Cerus’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.14) earnings per share. research analysts expect that Cerus will post -0.57 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in CERS. Elk Creek Partners LLC lifted its holdings in Cerus by 32.3% during the 2nd quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock worth $14,406,000 after buying an additional 1,402,106 shares during the last quarter. Ark Investment Management LLC lifted its holdings in shares of Cerus by 126.5% in the 2nd quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock worth $4,219,000 after purchasing an additional 938,647 shares during the last quarter. First Midwest Bank Trust Division lifted its holdings in shares of Cerus by 50.3% in the 3rd quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock worth $2,944,000 after purchasing an additional 360,785 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cerus by 3.9% in the 2nd quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after purchasing an additional 184,076 shares during the last quarter. Finally, Premier Asset Management LLC bought a new stake in shares of Cerus in the 3rd quarter worth approximately $348,000. 55.72% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Cerus (NASDAQ:CERS) Lifted to Sell at BidaskClub” was first published by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/cerus-cers-lifted-to-sell-at-bidaskclub/1820778.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.